Physiological effects of ivabradine in heart failure and beyond

被引:3
作者
Iness, Audra N. [1 ]
Shah, Keyur M. [2 ]
Kukreja, Rakesh C. [2 ]
机构
[1] Baylor Coll Med, Dept Pediat, Houston, TX USA
[2] Virginia Commonwealth Univ, Pauley Heart Ctr, Div Cardiol, Internal Med, Richmond, VA 23284 USA
基金
美国国家卫生研究院;
关键词
Heart failure; Sinoatrial node; Ischemia; Ivabradine; Funny current; CORONARY-ARTERY-DISEASE; CURRENT INHIBITOR IVABRADINE; F-CHANNEL INHIBITOR; RATE REDUCTION; I-F; BRADYCARDIAC AGENT; DOUBLE-BLIND; MYOCARDIAL-ISCHEMIA; PROGNOSTIC VALUE; STABLE ANGINA;
D O I
10.1007/s11010-023-04862-5
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Ivabradine is a pharmacologic agent that inhibits the funny current responsible for determining heart rate in the sinoatrial node. Ivabradine's clinical potential has been investigated in the context of heart failure since it is associated with reduced myocardial oxygen demand, enhanced diastolic filling, stroke volume, and coronary perfusion time; however, it is yet to demonstrate definitive mortality benefit. Alternative effects of ivabradine include modulation of the renin-angiotensin-aldosterone system, sympathetic activation, and endothelial function. Here, we review key clinical trials informing the clinical use of ivabradine and explore opportunities for leveraging its potential pleiotropic effects in other diseases, including treatment of hyperadrenergic states and mitigating complications of COVID-19 infection.
引用
收藏
页码:2405 / 2414
页数:10
相关论文
共 93 条
  • [1] Risk following hospitalization in stable chronic systolic heart failure
    Abrahamsson, Putte
    Swedberg, Karl
    Borer, Jeffrey S.
    Boehm, Michael
    Kober, Lars
    Komajda, Michel
    Lloyd, Suzanne M.
    Metra, Marco
    Tavazzi, Luigi
    Ford, Ian
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (08) : 885 - 891
  • [2] HYPERINSULINEMIA PRODUCES BOTH SYMPATHETIC NEURAL ACTIVATION AND VASODILATION IN NORMAL HUMANS
    ANDERSON, EA
    HOFFMAN, RP
    BALON, TW
    SINKEY, CA
    MARK, AL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) : 2246 - 2252
  • [3] SUBSETS OF AMBULATORY MYOCARDIAL-ISCHEMIA BASED ON HEART-RATE ACTIVITY - CIRCADIAN DISTRIBUTION AND RESPONSE TO ANTIISCHEMIC MEDICATION
    ANDREWS, TC
    FENTON, T
    TOYOSAKI, N
    GLASSER, SP
    YOUNG, PM
    MACCALLUM, G
    GIBSON, RS
    SHOOK, TL
    STONE, PH
    [J]. CIRCULATION, 1993, 88 (01) : 92 - 100
  • [4] Myocardial injury and COVID-19: Possible mechanisms
    Babapoor-Farrokhran, Savalan
    Gill, Deanna
    Walker, Jackson
    Rasekhi, Roozbeh Tarighati
    Bozorgnia, Behnam
    Amanullah, Aman
    [J]. LIFE SCIENCES, 2020, 253
  • [5] Absence of respiratory effects with ivabradine in patients with asthma
    Babu, K. Suresh
    Gadzik, Frantisek
    Holgate, Stephen T.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (01) : 96 - 101
  • [6] Ivabradine and the SIGNIFY conundrum
    Beltrame, John F.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3297 - 3299
  • [7] Preclinical results with If current inhibition by ivabradine
    Berdeaux, Alain
    [J]. DRUGS, 2007, 67 (Suppl 2) : 25 - 33
  • [8] COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart
    Bois, Melanie C.
    Boire, Nicholas A.
    Layman, Andrew J.
    Aubry, Marie-Christine
    Alexander, Mariam P.
    Roden, Anja C.
    Hagen, Catherine E.
    Quinton, Reade A.
    Larsen, Christopher
    Erben, Young
    Majumdar, Ramanath
    Jenkins, Sarah M.
    Kipp, Benjamin R.
    Lin, Peter T.
    Maleszewski, Joseph J.
    [J]. CIRCULATION, 2021, 143 (03) : 230 - 243
  • [9] Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells
    Bois, P
    Bescond, J
    Renaudon, B
    Lenfant, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) : 1051 - 1057
  • [10] Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina -: A randomized, double-blind, multicentered, placebo-controlled trial
    Borer, JS
    Fox, K
    Jaillon, P
    Lerebours, G
    [J]. CIRCULATION, 2003, 107 (06) : 817 - 823